title: Influence of apixaban on antifactor Xa levels in a patient with acute kidney injury.
abstract: OBJECTIVE
  The case of a patient requiring conversion from apixaban to heparin in the setting of acute kidney injury is reported.
  
  
  CONCLUSIONS
  A 70-year-old man was initiated on apixaban 5 mg twice daily for new-onset, nonvalvular atrial fibrillation with a CHA2DS2-VASc score of 4, indicating a high risk of stroke. Soon after starting apixaban, he experienced pulmonary edema with pneumonia requiring hospitalization. During the course of hospitalization, the patient developed acute kidney injury requiring hemodialysis, and apixaban was stopped due to concerns about altered pharmacokinetics and impaired drug elimination in this setting. A heparin infusion was started 36 hours after the last dose of apixaban was administered. Antifactor Xa levels were monitored consistent with the hospital's standard practice protocols. The initial and repeat antifactor Xa concentrations were elevated (1.8-4.4 IU/mL) for up 72 hours after stopping the heparin infusion. Given the suspected interference of apixaban with standard antifactor Xa level monitoring, the heparin protocol was modified to reflect drip-rate adjustments based on activated partial thromboplastin times (aPTTs). The hospital protocol for heparin infusions was reinstituted on hospital day 7, with dosage adjustments based on antifactor Xa levels. The patient remained on a continuous heparin infusion for atrial fibrillation for the remainder of his hospitalization without complications or bleeding events.
  
  
  CONCLUSIONS
  A 70-year-old man with new-onset nonvalvular atrial fibrillation and receiving apixaban discontinued this therapy and was given heparin instead due to acute kidney injury. His heparin dosage was successfully adjusted based on antifactor Xa levels and aPPTs.
authors.affiliation: Avera McKennan Hospital, Sioux Falls, SD, and Pharmacy Department, University Health Center, Sioux Falls, SD. jodi.wendte@avera.org.
authors.forename: Jodi
authors.initials: J
authors.lastname: Wendte
authors.affiliation: Avera McKennan Hospital, Sioux Falls, SD, and Pharmacy Department, University Health Center, Sioux Falls, SD.
authors.forename: Glenn
authors.initials: G
authors.lastname: Voss
authors.affiliation: Avera McKennan Hospital, Sioux Falls, SD, and Pharmacy Department, University Health Center, Sioux Falls, SD.
authors.forename: Beau
authors.initials: B
authors.lastname: VanOverschelde
mesh_terms: D058186:Acute Kidney Injury / Q000503:physiopathology* / Q000628:therapy; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage; D001281:Atrial Fibrillation / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D015951:Factor Xa / Q000032:analysis; D065427:Factor Xa Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D008297:Male; D011720:Pyrazoles / Q000008:administration & dosage* / Q000493:pharmacokinetics; D011728:Pyridones / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006435:Renal Dialysis
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D011720:Pyrazoles; D011728:Pyridones; C522181:apixaban; D006493:Heparin; D015951:Factor Xa